- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Neumora Therapeutics, Inc.: Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 | 4 | GlobeNewswire (USA) | ||
| 04.03. | Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 | 6 | Insider Monkey | ||
| 17.02. | Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment | 12 | Benzinga.com | ||
| 11.02. | Neumora Therapeutics, Inc. - 8-K, Current Report | 27 | SEC Filings | ||
| 04.02. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | 5 | GlobeNewswire (USA) | ||
| 12.01. | Neumora Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Leerink Partners initiates coverage on Neumora stock with Outperform rating | 10 | Investing.com | ||
| 07.01. | Mizuho bestätigt Outperform-Rating für Neumora nach starkem Kurssprung | 15 | Investing.com Deutsch | ||
| NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.01. | Mizuho reiterates Outperform rating on Neumora Therapeutics stock | 2 | Investing.com | ||
| 05.01. | Neumora's Alzheimer's Agitation Drug Shows Early Promise | 10 | Benzinga.com | ||
| 05.01. | Mizuho raises Neumora Therapeutics stock price target on positive trial data | 7 | Investing.com | ||
| 05.01. | Neumora gains after early-stage trial results for Alzheimer's product | 4 | Seeking Alpha | ||
| 05.01. | Neumora outlines 2026 pipeline milestones for neuroscience programs | 2 | Investing.com | ||
| 05.01. | Neumora Therapeutics, Inc.: Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones | 263 | GlobeNewswire (Europe) | Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to... ► Artikel lesen | |
| 05.01. | Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation | 206 | GlobeNewswire (Europe) | NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified... ► Artikel lesen | |
| 05.01. | Neumora Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.12.25 | Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset | 14 | Seeking Alpha | ||
| 01.12.25 | Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline | 16 | Benzinga.com | ||
| 01.12.25 | Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential | 3 | Investing.com | ||
| 21.11.25 | Neumora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,30 | +0,26 % | Bioxyne vs. BioNTech: Australisches MDMA-Biotech hebt Prognose nach starkem Halbjahr an | ||
| MODERNA | 44,100 | -0,54 % | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | ||
| AMGEN | 298,60 | -0,85 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| NOVAVAX | 8,315 | -0,50 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 157,75 | -0,25 % | Biogen Inc.: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 | TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
| ILLUMINA | 107,32 | -0,24 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | +1,50 % | Is CRISPR Therapeutics Stock a Buy Now? | ||
| MAINZ BIOMED | 0,526 | -8,52 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| INTELLIA THERAPEUTICS | 11,120 | -0,54 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 40,800 | 0,00 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,404 | -2,87 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| BIOMARIN PHARMACEUTICAL | 46,690 | -0,17 % | BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO | ||
| SAREPTA THERAPEUTICS | 14,710 | +1,62 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| EXELIXIS | 35,900 | +0,67 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen |
Das Unternehmen NEUMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,510 Euro und damit -3,09 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.